This technology is a library of SARS-CoV-2 specific nanobodies for the treatment, diagnosis, and prophylaxis of COVID-19.
SARS-CoV-2 is a global public health issue with new variants persistently emerging, demonstrating a need for preventative and therapeutic agents capable of a wide range of recognition while remaining robust and effective. Although monoclonal antibodies have been considered as diagnostics and/or therapeutics, particularly ones that bind the viral spike protein of SARS-CoV-2 or the human angiotensin converting enzyme 2 (ACE2) receptor, they can lack in reactivity, stability, and ease of delivery.
This platform provides a library of human IgG nanobodies against SARS-CoV-2 and its variants. Using previously reported methods for the immunization, isolation, and cloning of nanobodies, this platform will be used to develop nanobodies for the treatment, diagnosis, or prophylaxis of COVID-19. Moreover, the library is designed with a broad repertoire of epitope recognition, encompassing reactivity against a large family of SARS-CoV-2 variants, demonstrating potential benefits over the use of monoclonal antibodies.
Patent Pending([WO/20222/66235][(https://patents.google.com/patent/WO2022266235A1/en?oq=PCT%2fUS2022%2f033651))
IR CU21304
Licensing Contact: Kristin Neuman